By Karen E. Roman
Promontory Therapeutics Inc., a clinical stage development company centered on small molecule immunotherapy in cancer, presented its latest results on its lead therapeutic candidate, PT-112.
The results were exposed at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, from November 1-5, 2023.
Data shows PT-112 has the ability to induce immunogenic cell death (ICD) in cancer cells, which is mediated by endoplasmic reticulum (ER) and mitochondrial stresses.
PT-112 is in Phase 2 trials for late-stage metastatic castration-resistant prostate cancer and thymic epithelial tumors, a rare disease with no approved drug by the FDA and for which PT-112 has received FDA Orphan Drug designation.
“This particular work sheds light on how PT-112 encourages the immunogenic cell death of cancerous cells through ER stress and mitochondrial dysfunction, both of which are known to contribute to immune signaling,” stated Dr. Tyler Ames, the company’s Senior Vice President of R&D.